Artal Group’s Kyntra Bio KYNB Stock Holding History

Artal Group’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,000	Closed	-$6.94M	–	110
2018 Q4	$6.94M	Buy	+6,000	New	+$6.74M	0.26%	58

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group's KYNB Position: Q1 2021 in Review

Artal Group sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 16,000 shares — an estimated $14.8M sold.

Artal Group first reported a position in KYNB in Q3 2017 and held it in 13 quarters. The position peaked at $20.9M in Q1 2020. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

Artal Group reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
Artal Group sold 16,000 Kyntra Bio shares in Q1 2021, an estimated $14.8M.
Artal Group first reported a position in Kyntra Bio in Q3 2017 and held it in 13 quarters.
Artal Group's Kyntra Bio position peaked at $20.9M in Q1 2020.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.